← Becton Dickinson and overview

Becton Dickinson and vs Repligen: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Becton Dickinson and Company (BDX)

Q3 2026
▲4

BD Beats Q3, Expands GLP-1 Delivery and U.S. Manufacturing

  • Q3 earnings and revenue beat BD reported Q3 adjusted EPS of $3.23 and revenue of $4.98 billion, both above estimates, with growth across all four segments. The beat and narrowed full-year guidance reassured investors, pushing shares up nearly 7% and supporting the stock price.

    This is the core financial result that directly moved BDX shares and confirms business momentum.

  • GLP-1 delivery partnerships BD announced new GLP-1 delivery partnerships, including a semaglutide pen collaboration in Brazil using its Vystra Injection Pen platform. This opens a growing market for chronic disease treatment, boosting future revenue prospects and investor optimism.

    It highlights a new growth avenue that can drive future sales and supports the positive stock reaction.

  • Vmax 160 pharmacy robot deployment BD deployed its next-generation Vmax 160 pharmacy automation robot at Fairview Health Services, the first U.S. health system to adopt it. This showcases BD's technology leadership in pharmacy automation, potentially driving future orders and lifting the stock.

    It demonstrates product innovation and adoption, a positive signal for future revenue and competitive positioning.

  • $19 billion U.S. manufacturing expansion and tariff shield BD pledged $19 billion to expand U.S. manufacturing, including $3 billion for facilities, and secured an agreement that shields it from future Section 232 tariffs on specified products. This reduces tariff risk and strengthens domestic supply chain, supporting the stock.

    It addresses a major external risk (tariffs) and shows long-term commitment, directly impacting BDX's cost structure and pricing power.

September 2026
▲4

BD Beats Q3, Expands GLP-1 Delivery and U.S. Manufacturing

  • Q3 earnings and revenue beat BD reported Q3 adjusted EPS of $3.23 and revenue of $4.98 billion, both above estimates, with growth across all four segments. The beat and narrowed full-year guidance reassured investors, pushing shares up nearly 7% and supporting the stock price.

    This is the core financial result that directly moved BDX shares and confirms business momentum.

  • GLP-1 delivery partnerships BD announced new GLP-1 delivery partnerships, including a semaglutide pen collaboration in Brazil using its Vystra Injection Pen platform. This opens a growing market for chronic disease treatment, boosting future revenue prospects and investor optimism.

    It highlights a new growth avenue that can drive future sales and supports the positive stock reaction.

  • Vmax 160 pharmacy robot deployment BD deployed its next-generation Vmax 160 pharmacy automation robot at Fairview Health Services, the first U.S. health system to adopt it. This showcases BD's technology leadership in pharmacy automation, potentially driving future orders and lifting the stock.

    It demonstrates product innovation and adoption, a positive signal for future revenue and competitive positioning.

  • $19 billion U.S. manufacturing expansion and tariff shield BD pledged $19 billion to expand U.S. manufacturing, including $3 billion for facilities, and secured an agreement that shields it from future Section 232 tariffs on specified products. This reduces tariff risk and strengthens domestic supply chain, supporting the stock.

    It addresses a major external risk (tariffs) and shows long-term commitment, directly impacting BDX's cost structure and pricing power.

Latest
▲4

BD Beats Q3, Expands GLP-1 Delivery and U.S. Manufacturing

  • Q3 earnings and revenue beat BD reported Q3 adjusted EPS of $3.23 and revenue of $4.98 billion, both above estimates, with growth across all four segments. The beat and narrowed full-year guidance reassured investors, pushing shares up nearly 7% and supporting the stock price.

    This is the core financial result that directly moved BDX shares and confirms business momentum.

  • GLP-1 delivery partnerships BD announced new GLP-1 delivery partnerships, including a semaglutide pen collaboration in Brazil using its Vystra Injection Pen platform. This opens a growing market for chronic disease treatment, boosting future revenue prospects and investor optimism.

    It highlights a new growth avenue that can drive future sales and supports the positive stock reaction.

  • Vmax 160 pharmacy robot deployment BD deployed its next-generation Vmax 160 pharmacy automation robot at Fairview Health Services, the first U.S. health system to adopt it. This showcases BD's technology leadership in pharmacy automation, potentially driving future orders and lifting the stock.

    It demonstrates product innovation and adoption, a positive signal for future revenue and competitive positioning.

  • $19 billion U.S. manufacturing expansion and tariff shield BD pledged $19 billion to expand U.S. manufacturing, including $3 billion for facilities, and secured an agreement that shields it from future Section 232 tariffs on specified products. This reduces tariff risk and strengthens domestic supply chain, supporting the stock.

    It addresses a major external risk (tariffs) and shows long-term commitment, directly impacting BDX's cost structure and pricing power.

Repligen Corporation (RGEN)

Q3 2026
▲3

Repligen Buys BioLife, Beats Q2, Raises Guidance

  • Repligen to acquire BioLife Solutions for $1.5B Repligen agreed to buy BioLife Solutions for about $1.5 billion in cash and stock. The deal is expected to boost revenue growth, profit margins, and earnings per share, with $20–30 million in cost savings. This signals growth and makes the company more valuable.

    This is the biggest new event driving RGEN's price, showing a major growth move.

  • Q2 revenue beats estimates, full-year guidance raised Repligen reported Q2 revenue of $204.1 million, beating expectations, and adjusted EPS of $0.54, a 20% beat. The company raised full-year revenue and EPS guidance. Organic growth accelerated to 13%. This shows the business is performing better than expected, pushing the stock up.

    This is a fresh, positive earnings surprise that directly lifts investor confidence and the stock price.

  • Biotech stocks hit 52-week highs on deal news Several biotech stocks reached 52-week highs, helped by Repligen's BioLife acquisition announcement. BioLife shares jumped over 6%. This positive sector sentiment can lift Repligen's stock as investors see strength in the industry.

    It shows the acquisition is part of a broader positive trend, reinforcing the stock's upward move.

  • Trump announces phased tariffs on generic drug imports President Trump announced tariffs on generic drug imports, starting at zero for two years, then rising to 100% in 2028 and 200% in 2029. This could raise costs for biopharma companies and disrupt supply chains, but may also encourage onshore manufacturing, which could benefit Repligen's bioprocessing business.

    This is a new policy risk that could affect Repligen's customers and demand, creating uncertainty.

July 2026
▲3

Repligen Buys BioLife, Beats Q2, Raises Guidance

  • Repligen to acquire BioLife Solutions for $1.5B Repligen agreed to buy BioLife Solutions for about $1.5 billion in cash and stock. The deal is expected to boost revenue growth, profit margins, and earnings per share, with $20–30 million in cost savings. This signals growth and makes the company more valuable.

    This is the biggest new event driving RGEN's price, showing a major growth move.

  • Q2 revenue beats estimates, full-year guidance raised Repligen reported Q2 revenue of $204.1 million, beating expectations, and adjusted EPS of $0.54, a 20% beat. The company raised full-year revenue and EPS guidance. Organic growth accelerated to 13%. This shows the business is performing better than expected, pushing the stock up.

    This is a fresh, positive earnings surprise that directly lifts investor confidence and the stock price.

  • Biotech stocks hit 52-week highs on deal news Several biotech stocks reached 52-week highs, helped by Repligen's BioLife acquisition announcement. BioLife shares jumped over 6%. This positive sector sentiment can lift Repligen's stock as investors see strength in the industry.

    It shows the acquisition is part of a broader positive trend, reinforcing the stock's upward move.

  • Trump announces phased tariffs on generic drug imports President Trump announced tariffs on generic drug imports, starting at zero for two years, then rising to 100% in 2028 and 200% in 2029. This could raise costs for biopharma companies and disrupt supply chains, but may also encourage onshore manufacturing, which could benefit Repligen's bioprocessing business.

    This is a new policy risk that could affect Repligen's customers and demand, creating uncertainty.

Latest
▲3

Repligen Buys BioLife, Beats Q2, Raises Guidance

  • Repligen to acquire BioLife Solutions for $1.5B Repligen agreed to buy BioLife Solutions for about $1.5 billion in cash and stock. The deal is expected to boost revenue growth, profit margins, and earnings per share, with $20–30 million in cost savings. This signals growth and makes the company more valuable.

    This is the biggest new event driving RGEN's price, showing a major growth move.

  • Q2 revenue beats estimates, full-year guidance raised Repligen reported Q2 revenue of $204.1 million, beating expectations, and adjusted EPS of $0.54, a 20% beat. The company raised full-year revenue and EPS guidance. Organic growth accelerated to 13%. This shows the business is performing better than expected, pushing the stock up.

    This is a fresh, positive earnings surprise that directly lifts investor confidence and the stock price.

  • Biotech stocks hit 52-week highs on deal news Several biotech stocks reached 52-week highs, helped by Repligen's BioLife acquisition announcement. BioLife shares jumped over 6%. This positive sector sentiment can lift Repligen's stock as investors see strength in the industry.

    It shows the acquisition is part of a broader positive trend, reinforcing the stock's upward move.

  • Trump announces phased tariffs on generic drug imports President Trump announced tariffs on generic drug imports, starting at zero for two years, then rising to 100% in 2028 and 200% in 2029. This could raise costs for biopharma companies and disrupt supply chains, but may also encourage onshore manufacturing, which could benefit Repligen's bioprocessing business.

    This is a new policy risk that could affect Repligen's customers and demand, creating uncertainty.